ESR1 gene amplification and MAP3K mutations are selected during adjuvant endocrine therapies in relapsing Hormone Receptor-positive, HER2-negative breast cancer (HR+ HER2- BC).
Saved in:
| Title: | ESR1 gene amplification and MAP3K mutations are selected during adjuvant endocrine therapies in relapsing Hormone Receptor-positive, HER2-negative breast cancer (HR+ HER2- BC). |
|---|---|
| Authors: | Ferrando L; IRCCS Ospedale Policlinico San Martino, Genova, Italy., Vingiani A; Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy., Garuti A; IRCCS Ospedale Policlinico San Martino, Genova, Italy., Vernieri C; Department of Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.; IFOM, The FIRC Institute of Molecular Oncology, Milan, Italy., Belfiore A; Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Agnelli L; Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Dagrada G; Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Ivanoiu D; Department of Surgery and Cancer, Imperial College London, London, United Kingdom., Bonizzi G; Department of Pathology, IEO European Institute of Oncology IRCCS, Milan, Italy., Munzone E; Division of Medical Senology, IEO European Institute of Oncology IRCCS, Milan, Italy., Lippolis L; Division of Pathology, Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico, Milan, Italy., Dameri M; Department of Internal Medicine (DiMI), University of Genoa, Genova, Italy., Ravera F; Department of Internal Medicine (DiMI), University of Genoa, Genova, Italy., Colleoni M; Division of Medical Senology, IEO European Institute of Oncology IRCCS, Milan, Italy., Viale G; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.; Department of Pathology, IEO European Institute of Oncology IRCCS, Milan, Italy., Magnani L; Department of Surgery and Cancer, Imperial College London, London, United Kingdom., Ballestrero A; IRCCS Ospedale Policlinico San Martino, Genova, Italy.; Department of Internal Medicine (DiMI), University of Genoa, Genova, Italy., Zoppoli G; IRCCS Ospedale Policlinico San Martino, Genova, Italy.; Department of Internal Medicine (DiMI), University of Genoa, Genova, Italy., Pruneri G; Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy. |
| Source: | PLoS genetics [PLoS Genet] 2023 Jan 03; Vol. 19 (1), pp. e1010563. Date of Electronic Publication: 2023 Jan 03 (Print Publication: 2023). |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Public Library of Science Country of Publication: United States NLM ID: 101239074 Publication Model: eCollection Cited Medium: Internet ISSN: 1553-7404 (Electronic) Linking ISSN: 15537390 NLM ISO Abbreviation: PLoS Genet Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 36595552 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: ESR1 gene amplification and MAP3K mutations are selected during adjuvant endocrine therapies in relapsing Hormone Receptor-positive, HER2-negative breast cancer (HR+ HER2- BC). – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Ferrando+L%22">Ferrando L</searchLink>; IRCCS Ospedale Policlinico San Martino, Genova, Italy.<br /><searchLink fieldCode="AU" term="%22Vingiani+A%22">Vingiani A</searchLink>; Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.<br /><searchLink fieldCode="AU" term="%22Garuti+A%22">Garuti A</searchLink>; IRCCS Ospedale Policlinico San Martino, Genova, Italy.<br /><searchLink fieldCode="AU" term="%22Vernieri+C%22">Vernieri C</searchLink>; Department of Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.; IFOM, The FIRC Institute of Molecular Oncology, Milan, Italy.<br /><searchLink fieldCode="AU" term="%22Belfiore+A%22">Belfiore A</searchLink>; Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.<br /><searchLink fieldCode="AU" term="%22Agnelli+L%22">Agnelli L</searchLink>; Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.<br /><searchLink fieldCode="AU" term="%22Dagrada+G%22">Dagrada G</searchLink>; Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.<br /><searchLink fieldCode="AU" term="%22Ivanoiu+D%22">Ivanoiu D</searchLink>; Department of Surgery and Cancer, Imperial College London, London, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Bonizzi+G%22">Bonizzi G</searchLink>; Department of Pathology, IEO European Institute of Oncology IRCCS, Milan, Italy.<br /><searchLink fieldCode="AU" term="%22Munzone+E%22">Munzone E</searchLink>; Division of Medical Senology, IEO European Institute of Oncology IRCCS, Milan, Italy.<br /><searchLink fieldCode="AU" term="%22Lippolis+L%22">Lippolis L</searchLink>; Division of Pathology, Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico, Milan, Italy.<br /><searchLink fieldCode="AU" term="%22Dameri+M%22">Dameri M</searchLink>; Department of Internal Medicine (DiMI), University of Genoa, Genova, Italy.<br /><searchLink fieldCode="AU" term="%22Ravera+F%22">Ravera F</searchLink>; Department of Internal Medicine (DiMI), University of Genoa, Genova, Italy.<br /><searchLink fieldCode="AU" term="%22Colleoni+M%22">Colleoni M</searchLink>; Division of Medical Senology, IEO European Institute of Oncology IRCCS, Milan, Italy.<br /><searchLink fieldCode="AU" term="%22Viale+G%22">Viale G</searchLink>; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.; Department of Pathology, IEO European Institute of Oncology IRCCS, Milan, Italy.<br /><searchLink fieldCode="AU" term="%22Magnani+L%22">Magnani L</searchLink>; Department of Surgery and Cancer, Imperial College London, London, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Ballestrero+A%22">Ballestrero A</searchLink>; IRCCS Ospedale Policlinico San Martino, Genova, Italy.; Department of Internal Medicine (DiMI), University of Genoa, Genova, Italy.<br /><searchLink fieldCode="AU" term="%22Zoppoli+G%22">Zoppoli G</searchLink>; IRCCS Ospedale Policlinico San Martino, Genova, Italy.; Department of Internal Medicine (DiMI), University of Genoa, Genova, Italy.<br /><searchLink fieldCode="AU" term="%22Pruneri+G%22">Pruneri G</searchLink>; Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101239074%22">PLoS genetics</searchLink> [PLoS Genet] 2023 Jan 03; Vol. 19 (1), pp. e1010563. <i>Date of Electronic Publication: </i>2023 Jan 03 (<i>Print Publication: </i>2023). – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Research Support, Non-U.S. Gov't – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Public+Library+of+Science%22">Public Library of Science </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101239074 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Internet <i>ISSN: </i>1553-7404 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2215537390%22">15537390 </searchLink><i>NLM ISO Abbreviation: </i>PLoS Genet <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=36595552 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1371/journal.pgen.1010563 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: e1010563 Titles: – TitleFull: ESR1 gene amplification and MAP3K mutations are selected during adjuvant endocrine therapies in relapsing Hormone Receptor-positive, HER2-negative breast cancer (HR+ HER2- BC). Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Ferrando L – PersonEntity: Name: NameFull: Vingiani A – PersonEntity: Name: NameFull: Garuti A – PersonEntity: Name: NameFull: Vernieri C – PersonEntity: Name: NameFull: Belfiore A – PersonEntity: Name: NameFull: Agnelli L – PersonEntity: Name: NameFull: Dagrada G – PersonEntity: Name: NameFull: Ivanoiu D – PersonEntity: Name: NameFull: Bonizzi G – PersonEntity: Name: NameFull: Munzone E – PersonEntity: Name: NameFull: Lippolis L – PersonEntity: Name: NameFull: Dameri M – PersonEntity: Name: NameFull: Ravera F – PersonEntity: Name: NameFull: Colleoni M – PersonEntity: Name: NameFull: Viale G – PersonEntity: Name: NameFull: Magnani L – PersonEntity: Name: NameFull: Ballestrero A – PersonEntity: Name: NameFull: Zoppoli G – PersonEntity: Name: NameFull: Pruneri G IsPartOfRelationships: – BibEntity: Dates: – D: 03 M: 01 Text: 2023 Jan 03 Type: published Y: 2023 Identifiers: – Type: issn-electronic Value: 1553-7404 Numbering: – Type: volume Value: 19 – Type: issue Value: 1 Titles: – TitleFull: PLoS genetics Type: main |
| ResultId | 1 |
